Virax Biolabs Group Ltd Financials
This page shows Virax Biolabs Group Ltd (VRAX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Virax’s dominant mechanic is equity-funded cash burn: commercial activity is minimal while the balance sheet is repeatedly refilled from financing.
FY2025 ended with$4.2M of cash, but operations consumed$4.6M , so the company did not self-fund even one year of activity from customers or recurring cash generation. That dependence looks structural rather than temporary because financing brought in$1.6M in one year and$5.8M in the next while reported sales remained too small to absorb the overhead base.
Sales are not yet the operating center: revenue was only
Short-term liquidity looks comfortable because cash exceeds current liabilities by about 6.3x, and debt is only
Financial Health Signals
We are recalculating Virax Biolabs Group Ltd's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Virax Biolabs Group Ltd passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Virax Biolabs Group Ltd generates $0.92 in operating cash flow (-$4.6M OCF vs -$5.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Virax Biolabs Group Ltd generated $12K in revenue in fiscal year 2026. This represents an increase of 96.2% from the prior year.
Virax Biolabs Group Ltd reported -$5.0M in net income in fiscal year 2026. This represents an increase of 17.1% from the prior year.
Cash & Balance Sheet
Virax Biolabs Group Ltd generated -$4.9M in free cash flow in fiscal year 2026, representing cash available after capex. This represents an increase of 5.6% from the prior year.
Virax Biolabs Group Ltd held $4.2M in cash against $305K in long-term debt as of fiscal year 2026.
Virax Biolabs Group Ltd had 579,218 shares outstanding in fiscal year 2026.
Margins & Returns
Virax Biolabs Group Ltd's net profit margin was -40507.0% in fiscal year 2026, showing the share of revenue converted to profit. This is up 55326.7 percentage points from the prior year.
Virax Biolabs Group Ltd's ROE was -68.6% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 42.5 percentage points from the prior year.
Capital Allocation
Virax Biolabs Group Ltd invested $256K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 57.6% from the prior year.
VRAX Income Statement
| Metric | Q3'25 | Q3'24 | Q3'23 | Q3'22 | Q3'21 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A |
VRAX Balance Sheet
| Metric | Q3'25 | Q3'24 | Q3'23 | Q3'22 | Q3'21 |
|---|---|---|---|---|---|
| Total Assets | $6.4M+17.2% | $5.5M-44.1% | $9.8M+20046.2% | $49K+22.9% | $40K |
| Current Assets | $4.9M+11.7% | $4.4M-54.5% | $9.6M+19679.9% | $49K+22.9% | $40K |
| Cash & Equivalents | $4.2M+17.8% | $3.6M-61.6% | $9.4M+42888.3% | $22K+23.5% | $18K |
| Inventory | $95K+56.8% | $60K | $0-100.0% | $21K-0.6% | $21K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | $178K | N/A | N/A |
| Total Liabilities | $965K+179.5% | $345K-62.0% | $908K-27.1% | $1.2M+42.9% | $871K |
| Current Liabilities | $673K+298.7% | $169K-81.4% | $908K-27.1% | $1.2M+42.9% | $871K |
| Long-Term Debt | $292K+65.3% | $176K | N/A | N/A | N/A |
| Total Equity | $5.5M+6.3% | $5.1M-42.3% | $8.9M+844.0% | -$1.2M-43.9% | -$832K |
| Retained Earnings | -$24.6M-32.7% | -$18.5M-57.1% | -$11.8M-86.1% | -$6.3M-36.9% | -$4.6M |
VRAX Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q3'23 | Q3'22 | Q3'21 |
|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A |
VRAX Financial Ratios
| Metric | Q3'25 | Q3'24 | Q3'23 | Q3'22 | Q3'21 |
|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 7.27-18.7 | 25.94+15.3 | 10.61+10.6 | 0.040.0 | 0.05 |
| Debt-to-Equity | 0.05+0.0 | 0.03-0.1 | 0.10+1.1 | -1.040.0 | -1.05 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Virax Biolabs Group Ltd's annual revenue?
Virax Biolabs Group Ltd (VRAX) reported $12K in total revenue for fiscal year 2026. This represents a 96.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Virax Biolabs Group Ltd's revenue growing?
Virax Biolabs Group Ltd (VRAX) revenue grew by 96.2% year-over-year, from $6K to $12K in fiscal year 2026.
Is Virax Biolabs Group Ltd profitable?
No, Virax Biolabs Group Ltd (VRAX) reported a net income of -$5.0M in fiscal year 2026, with a net profit margin of -40507.0%.
How much debt does Virax Biolabs Group Ltd have?
As of fiscal year 2026, Virax Biolabs Group Ltd (VRAX) had $4.2M in cash and equivalents against $305K in long-term debt.
What is Virax Biolabs Group Ltd's net profit margin?
Virax Biolabs Group Ltd (VRAX) had a net profit margin of -40507.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Virax Biolabs Group Ltd's return on equity (ROE)?
Virax Biolabs Group Ltd (VRAX) has a return on equity of -68.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Virax Biolabs Group Ltd's free cash flow?
Virax Biolabs Group Ltd (VRAX) generated -$4.9M in free cash flow during fiscal year 2026. This represents a 5.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Virax Biolabs Group Ltd's operating cash flow?
Virax Biolabs Group Ltd (VRAX) generated -$4.6M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Virax Biolabs Group Ltd's total assets?
Virax Biolabs Group Ltd (VRAX) had $8.3M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Virax Biolabs Group Ltd's capital expenditures?
Virax Biolabs Group Ltd (VRAX) invested $256K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is Virax Biolabs Group Ltd's current ratio?
Virax Biolabs Group Ltd (VRAX) had a current ratio of 9.97 as of fiscal year 2026, which is generally considered healthy.
What is Virax Biolabs Group Ltd's debt-to-equity ratio?
Virax Biolabs Group Ltd (VRAX) had a debt-to-equity ratio of 0.04 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Virax Biolabs Group Ltd's return on assets (ROA)?
Virax Biolabs Group Ltd (VRAX) had a return on assets of -60.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Virax Biolabs Group Ltd's cash runway?
Based on fiscal year 2026 data, Virax Biolabs Group Ltd (VRAX) had $4.2M in cash against an annual operating cash burn of $4.6M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Virax Biolabs Group Ltd's Piotroski F-Score?
Virax Biolabs Group Ltd (VRAX) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Virax Biolabs Group Ltd's earnings high quality?
Virax Biolabs Group Ltd (VRAX) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.